Skip to main
CBIO

GlycoMimetics Inc (CBIO) Stock Forecast & Price Target

GlycoMimetics Inc (CBIO) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Crescent Biopharma Inc. has demonstrated a significant positive outlook due to the promising results from the HARMONi-A OS trial, which confirms that their modality can achieve meaningful survival advantages in a patient population where Keytruda is not the standard of care. The successful outcomes of the Phase 3 trial indicate that CR-001, a bispecific antibody, is capable of translating robust progression-free survival (PFS) benefits into overall survival advantages, positioning it favorably against competitive therapies. Furthermore, the lucrative partnership arrangements for similar drug classes suggest strong market potential and commercial opportunities for Crescent Biopharma, enhancing the company's financial prospects as it advances its drug pipeline.

Bears say

Crescent Biopharma faces significant risks that contribute to a negative outlook on its stock, particularly the potential for adverse events related to its lead program, CR-001, and its progression through clinical trials. Additionally, there are concerns about the possibility that CR-001 may demonstrate a notably inferior efficacy profile compared to competing therapies, which could hinder its success in the market. The existence of a valuation gap further complicates the financial outlook, indicating potential challenges in achieving expected revenue milestones.

GlycoMimetics Inc (CBIO) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GlycoMimetics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GlycoMimetics Inc (CBIO) Forecast

Analysts have given GlycoMimetics Inc (CBIO) a Strong Buy based on their latest research and market trends.

According to 5 analysts, GlycoMimetics Inc (CBIO) has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GlycoMimetics Inc (CBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.